OmniComm Systems is a provider of customer-driven Internet solutions to pharmaceutical, biotechnology, research, and medical device organizations that conduct clinical trial research both in the United States and Europe. It is one of the fastest growing companies in electronic data capture (EDC) marketplace today.
The company today announced that Veeda Clinical Research, Inc., also known as Veeda Oncology, has joined OmniComm’s CRO Preferred Program. As part of this program, Veeda Oncology has signed an agreement to run their first study through the program, a 27-month, phase I oncology trial. This complex study will utilize OmniComm’s TrailMaster EDC suite to manage their data collection, submission, and medical coding needs.
Veeda Oncology is a specialized global oncology clinical research organization capable of handling the rigors of phase I through phase IV trials. It is dedicated to providing comprehensive clinical oncology research services internationally for the pharmaceutical and biotechnology industries. It has offices located in the United States, Europe, India, and Malaysia.
Omnicomm’s CRO Preferred Program was chosen by Veeda because of the company’s experience and expertise in conducting oncology trials. And Veeda is not the first company to do so. The addition of Veeda Oncology brings the membership total in the Program to 48 clinical research organizations. They are drawn by members exclusive benefits including sales and marketing support, training and having a having a dedicated, hosted environment all at a fixed, pay-as-you-go price.
For additional information about OmniComm Systems and the services it offers, please visit the company’s website at www.OmniComm.com
Let us hear your thoughts below:
